论文库首页  论文库
 
论文编号:
论文题目: The Challenges and the Promise of Molecular Targeted Therapy in Malignant Gliomas
英文论文题目: The Challenges and the Promise of Molecular Targeted Therapy in Malignant Gliomas
第一作者: Wang, HX; Xu, T; Jiang, Y; Xu, HC; Yan, Y; Fu, D; Chen, JX
英文第一作者: Wang, HX; Xu, T; Jiang, Y; Xu, HC; Yan, Y; Fu, D; Chen, JX
联系作者: Chen, JX (reprint author), Shanghai Changzheng Hosp, 415 Fengyang Rd, Shanghai 200003, Peoples R China.
英文联系作者: Chen, JX (reprint author), Shanghai Changzheng Hosp, 415 Fengyang Rd, Shanghai 200003, Peoples R China.
外单位作者单位:
英文外单位作者单位:
发表年度: 2015
卷: 17
期: 3
页码: 239-255
摘要: Malignant gliomas are the most common malignant primary brain tumors and one of the most challenging forms of cancers to treat. Despite advances in conventional treatment, the outcome for patients remains almost universally fatal. This poor prognosis is due to therapeutic resistance and tumor recurrence after surgical removal. However, over the past decade, molecular targeted therapy has held the promise of transforming the care of malignant glioma patients. Significant progress in understanding the molecular pathology of gliomagenesis and maintenance of the malignant phenotypes will open opportunities to rationally develop new molecular targeted therapy options. Recently, therapeutic strategies have focused on targeting pro-growth signaling mediated by receptor tyrosine kinase/RAS/phosphatidylinositol 3-kinase pathway, proangiogenic pathways, and several other vital intracellular signaling networks, such as proteasome and histone deacetylase. However, several factors such as cross-talk between the altered pathways, intratumoral molecular heterogeneity, and therapeutic resistance of glioma stem cells (GSCs) have limited the activity of single agents. Efforts are ongoing to study in depth the complex molecular biology of glioma, develop novel regimens targeting GSCs, and identify biomarkers to stratify patients with the individualized molecular targeted therapy. Here, we review the molecular alterations relevant to the pathology of malignant glioma, review current advances in clinical targeted trials, and discuss the challenges, controversies, and future directions of molecular targeted therapy.
英文摘要: Malignant gliomas are the most common malignant primary brain tumors and one of the most challenging forms of cancers to treat. Despite advances in conventional treatment, the outcome for patients remains almost universally fatal. This poor prognosis is due to therapeutic resistance and tumor recurrence after surgical removal. However, over the past decade, molecular targeted therapy has held the promise of transforming the care of malignant glioma patients. Significant progress in understanding the molecular pathology of gliomagenesis and maintenance of the malignant phenotypes will open opportunities to rationally develop new molecular targeted therapy options. Recently, therapeutic strategies have focused on targeting pro-growth signaling mediated by receptor tyrosine kinase/RAS/phosphatidylinositol 3-kinase pathway, proangiogenic pathways, and several other vital intracellular signaling networks, such as proteasome and histone deacetylase. However, several factors such as cross-talk between the altered pathways, intratumoral molecular heterogeneity, and therapeutic resistance of glioma stem cells (GSCs) have limited the activity of single agents. Efforts are ongoing to study in depth the complex molecular biology of glioma, develop novel regimens targeting GSCs, and identify biomarkers to stratify patients with the individualized molecular targeted therapy. Here, we review the molecular alterations relevant to the pathology of malignant glioma, review current advances in clinical targeted trials, and discuss the challenges, controversies, and future directions of molecular targeted therapy.
刊物名称: NEOPLASIA
英文刊物名称: NEOPLASIA
论文全文:
英文论文全文:
全文链接:
其它备注:
英文其它备注:
学科: Oncology
英文学科: Oncology
影响因子: 4.252
第一作者所在部门:
英文第一作者所在部门:
论文出处:
英文论文出处:
论文类别: Review
英文论文类别: Review
参与作者:
英文参与作者:
 
2014 中国科学院上海生命科学研究院 版权所有